Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma's stock has experienced significant volatility in the past six months. The company's stock price increased by 139.43% over the last six months and 46.42% over the last three months. Positive results from its Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis led to a substantial surge in the stock price, with shares jumping 80% and reaching an all-time high of $29.73 on October 9, 2025. Insider buying activity has also been noted.

Direct demand seasonality for Zenas BioPharma's products is not explicitly detailed, likely due to its clinical-stage nature. Product demand would be driven by disease prevalence and treatment efficacy rather than seasonal cycles. There is some indication of stock seasonality, with October historically favoring a short bias for ZBIO.

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative immunology-based therapies for patients with autoimmune diseases, operating within the Biotechnology: Pharmaceutical Preparations industry. The company acquires product candidates and strategically deploys internal and external resources. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to inhibit the activity of cells implicated in autoimmune and inflammatory diseases. Zenas BioPharma is also developing ZB002, ZB004, and ZB001. Additionally, the company recently in-licensed orelabrutinib, which is being studied in a global Phase 3 clinical trial for Primary Progressive Multiple Sclerosis, with plans to initiate a global Phase 3 trial for Secondary Progressive Multiple Sclerosis in the first quarter of 2026.

Zenas BioPharma, Inc. is headquartered in Waltham, Massachusetts, United States. The company is committed to global development and commercialization, and the recent licensing agreement for orelabrutinib includes global development and commercialization rights.

Zenas BioPharma's reputation has been impacted by a securities class-action lawsuit filed in April 2025, alleging misleading disclosures in connection with its September 2024 IPO. However, the company's reputation has likely seen a positive shift due to the announcement of positive Phase 2 results for obexelimab in Relapsing Multiple Sclerosis in October 2025.

Zenas BioPharma, Inc. has a mixed ownership structure. Institutional investors hold approximately 55.96% to 77.12% of the company's stock, while insiders own around 16.50% to 17.70%, and retail investors hold about 3.92% to 5.18%. Major institutional shareholders include Sr One Capital Management, Lp, Enavate Sciences GP, LLC, Fmr Llc, NEA Management Company, LLC, Novo Holdings A/S, Fairmount Funds Management LLC, Federated Hermes, Inc., NVP Associates, LLC, Deerfield Management Company, L.p. (series C), and Vivo Capital, LLC. Jason Raleigh Nunn is noted as owning the most shares among individual investors.